7Â 5% of patients with relapsing-remitting multiple sclerosis (RRMS) and suboptimal response to prior treatment had no evidence of disease [...]
HERTFORDSHIRE, England, and PITTSBURGH– August 19, 2020 – Mylan N.V. (NASDAQ: MYL) today announced the launch of the first [...]
The US FDA has approved inebilizumab for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults who are anti-aquaporin-4 [...]
Sue Bennett with June Halper POSTPONEMENT Â Due to continued concerns regarding COVID, only a limited amount of people are able to [...]
In light of the COVID-19 pandemic and its impact on the MS community, please know the Multiple Sclerosis Association of American (MSAA) has [...]
Bristol Myers Squibb Announces Commercial Launch and Availability of ZEPOSIA® (ozanimod), a New Oral Treatment for Relapsing Forms of [...]
New 6-Year Data for Genentech’s Ocrevus (ocrelizumab) Show Earlier Treatment Initiation Nearly Halves Risk of Needing Walking Aid in [...]
